Why Procter & Gamble Q2 Earnings Were Not Enough

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why Procter & Gamble Q2 Earnings Were Not Enough

© courtesy of Procter & Gamble Co.

Procter & Gamble Co. (NYSE: PG) released its most recent quarterly results before the markets opened on Tuesday. The company posted $1.19 in earnings per share (EPS) and $17.4 billion in revenue, compared with consensus estimates from Thomson Reuters that called for $1.14 in EPS on revenue of $17.39 billion. The same period of last year reportedly had EPS of $1.08 and $16.86 billion in revenue.

During the quarter, the company tallied a provisional net charge of $628 million related to the Tax Cut and Jobs Act, comprised of an estimated repatriation tax charge of $3.8 billion (comprised of the U.S. repatriation taxes and foreign withholding taxes) and a net deferred tax benefit of roughly $3.2 billion.

P&G reported its quarterly results for its business segments as follows:

  • Beauty segment organic sales increased 9% to $3.23 billion.
  • Grooming segment organic sales decreased 3% to $1.78 billion.
  • Health Care segment increased organic sales 4% to $2.21 billion.
  • Fabric and Home Care segment organic sales increased 3% to $5.43 billion.
  • Baby, Feminine and Family Care segment organic sales decreased 1% to $4.61 billion.

[nativounit]

Looking ahead to the fiscal 2018 full year, the company expects to see core EPS up 5% to 8%, compared to in 2017. P&G also expects all-in sales growth of about 3% in the same time. The consensus estimates call for $4.18 in EPS and $67.05 billion in revenue for the 2018 fiscal year.

David Taylor, board chair, president and chief executive, kept it short and sweet:

We accelerated organic sales growth and delivered strong productivity cost savings and cash flow. We remain on track to achieve our fiscal year objectives.

Shares of Procter & Gamble traded down about 3% at $89.18 early Tuesday, with a consensus analyst price target of $93.84 and a 52-week range of $85.42 to $94.67.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618